Richard Fisher

Articles

Dr. Fisher on Bortezomib/R-CHOP Combo for Mantle Cell Lymphoma

January 7th 2015

Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.